重组人干扰素α/β受体2(IFNα/βR2)

特别提示：包括重组人干扰素α/β受体2(IFNα/βR2)在内，本公司的所有产品仅可用于科研实验，严禁用于临床医疗及其他非科研用途！

产品名称：重组人干扰素α/β受体2(IFNα/βR2)
英文名称：Recombinant Human Interferon alpha/beta Receptor 2
产品货号：JN1131
产品规格：10μg|50μg|500μg|1mg

本品由我们的哺乳动物细胞表达系统制备而成，目的基因编码的Ile27-Lys243在C端带有Fc标签。

IFN-alpha/beta R2质量控制：＞95%(还原性SDS-PAGE)

IFN-alpha/beta R2制剂：冻干品

IFN-alpha/beta R2保存：
冻干蛋白置于-20℃以下可长期保存，室温条件下可稳定保存3周。
复溶蛋白溶液可在4～7℃保存2～7天，可分装后置于-20℃保存三个月。

IFN-alpha/beta R2复溶：
打开试剂管前请先离心。
复溶浓度推荐大于100 μg/ml。
冻干蛋白请溶于ddH2O。
复溶后，请根据用量分装冻存，避免反复冻融。

关于IFN-alpha/beta R2：
Interferon α/β Receptor 2 (IFN-α/β R2) is a single-pass type I membrane protein which belongs to the type II cytokine receptor family. It complexes with IFN-α/β R1 to form the signaling receptor complex for the family of α and β IFN subtypes. By alternative splicing, IFN-α/β R2 can exist as a secreted soluble protein or as a type I membrane protein. IFN-α/β R2 is the principal ligand binding subunit of the receptor. Ligand binding is stabilized by the subsequent association with IFN-α/β R1, resulting in the formation of a signaling ternary receptor complex. IFNAR2 was detected in most lymphocytes, monocytes, and granulocytes, although IFNAR2 expression was higher in the monocytes and granulocytes than in the lymphocytes. Among the lymphocyte subsets, IFNAR2 showed high expression in natural killer (NK) cells and low expression in T lymphocytes. Isoform 1 and isoform 3 of IFNAR2 are directly involved in signal transduction due to their interaction with the TYR kinase, JAK1. Isoform 1 also interacts with the transcriptional factors, STAT1 and STAT2. Both forms are potent inhibitors of type I IFN activity.

除了重组人干扰素α/β受体2(IFNα/βR2),，我公司还供应以下相关产品：



名称：重组人VEGF-A(血管内皮生长因子A)(带His标签)
货号：JN0245
规格：10μg|50μg|500μg|1mg
本品由我们的哺乳动物表达系统制备，目的基因编码的Ala27-Arg147在C端含有His标签。

VEGF121质量控制：＞95%(还原性SDS-PAGE)。

VEGF121制剂：冻干品

VEGF121保存：
冻干蛋白可在-20℃长期保存，室温也可稳定保存3周。
复溶蛋白溶液可在4～7℃保存2～7天。
复溶后建议分装冻存在-20℃，可保存3个月，应避免反复冻融。

VEGF121复溶：
1、试剂开盖前请先离心。
2、复溶浓度应大于100 μg/ml.
3、冻干蛋白溶于ddH2O中
4、复溶后根据使用量分装保存，避免反复冻融。

关于VEGF121：
Human VEGF121, also known as Vascular endothelial growth factor A, VEGFA, Vascular permeability factor, VPF and VEGF, is a homodimeric, heparin-binding glycoprotein which belongs to the platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) family. VEGF-A is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis, permeabilization of blood vessels and endothelial cell growth, increasing microvascular permeability, promoting cell migration and inhibiting apoptosis. Alternatively spliced transcript variants of VEGF-A encod either secreted or cell-associated isoforms. The lymphangiogenesis may be promoted by upregulation of VEGF121, which may in turn act in part via induction of VEGF-C. It binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.